ArticleThe Journal of infectious diseases2018
Posttreatment HRP2 Clearance in Patients with Uncomplicated Plasmodium falciparum Malaria.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 84 citations in OpenAlex.
- Persistence of Plasmodium falciparum HRP-2 antigenaemia after artemisinin combination therapy is not associated with gametocytes.Malaria journal · 2022Trial
- Comparative evaluation of multiplex bead assay, polymerase chain reaction, and rapid diagnostic test for P. falciparum detection in community surveys in Malawi.Malaria journal · 2026Article
- Reevaluating malaria severity metrics: insights from PfHRP2-derived biomass estimates in Ghanaian children.Malaria journal · 2026Article
- First report of pfhrp2 and pfhrp3 gene deletions compromising HRP2-based malaria rapid diagnostic tests in Malawi.Infectious diseases of poverty · 2025Article
- Evidence-based decision making for malaria elimination applying the Freedom From Infection statistical framework in five malaria eliminating countries: an observational study.The Lancet. Global health · 2025Observational
- Article
- Principal component analysis of the Serological response to Plasmodium Falciparum using a Multiplex bead-based assay in Nigeria.Scientific reports · 2024Article
- Slow clearance of histidine-rich protein-2 in Gabonese with uncomplicated malaria.Microbiology spectrum · 2024Observational
- Malaria community case management usage and quality of malaria care in a moderate Plasmodium falciparum burden region of Chadiza District, Zambia.Malaria journal · 2024Article
- Malaria infection among adults residing in a highly endemic region from the Democratic Republic of the Congo.Malaria journal · 2024Article
- Estimation of parasitaemia in imported falciparum malaria using the results of a combined rapid diagnostic test. No big help from haematological parameters.Malaria journal · 2023Observational
- Performance ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- Plasmodium falciparum infection prevalence among children aged 6-59 months from independent DHS and HIV surveys: Nigeria, 2018.Scientific reports · 2023Article
- Performance of antigen detection for HRP2-based malaria rapid diagnostic tests in community surveys: Tanzania, July-November 2017.Malaria journal · 2022Article
- Diagnostic applications of microsphere-based flow cytometry: A review.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Factors Affecting the Performance of HRP2-Based Malaria Rapid Diagnostic Tests.Tropical medicine and infectious disease · 2022Review
- The in-vivo dynamics of Plasmodium falciparum HRP2: implications for the use of rapid diagnostic tests in malaria elimination.Malaria journal · 2022Article
- Sensitivity and specificity for malaria classification of febrile persons by rapid diagnostic test, microscopy, parasite DNA, histidine-rich protein 2, and IgG: Dakar, Senegal 2015.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Screening strategies and laboratory assays to support Plasmodium falciparum histidine-rich protein deletion surveillance: where we are and what is needed.Malaria journal · 2022Review
- Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 4 countries.
Funding
Abstract
Background: The response to antimalarial treatment is assessed using serial microscopy. New techniques for accurate measurement of the Plasmodium falciparum histidine-rich protein 2 (HRP2) antigen have allowed for monitoring of the antigen concentration over time, offering a potential alternative for assessing treatment response. Methods: Posttreatment HRP2 concentrations were measured in samples obtained longitudinally from 537 individuals with P. falciparum malaria who were participating in efficacy trials in Angola, Tanzania, and Senegal. The HRP2 half-life was estimated using a first-order kinetics clearance model. The association between the HRP2 concentration 3 days after treatment and recrudescence of infection was assessed. Results: Despite substantial variation in HRP2 concentrations among participants at baseline, concentrations consistently showed a first-order exponential decline. The median half-life of HRP2 was estimated to be 4.5 days (interquartile range [IQR], 3.3-6.6 days) in Angola, 4.7 days (IQR, 4.0-5.9 days) in Tanzania, and 3.0 days (IQR, 2.1-4.5 days) in Senegal. The day 3 HRP2 concentration was predictive of eventual recrudescence, with an area under the receiver operating characteristic curve of 0.86 (95% confidence interval, .73-.99). Conclusions: Consistent HRP2 clearance dynamics following successful antimalarial treatment imply a common underlying mechanism of biological clearance. Patients who ultimately did not respond to treatment did not exhibit this same pattern of clearance, even in the absence of other indications of inadequate response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.